# Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally

Source: https://onco.cc/trials/nct07104604/  
OnCo record `nct07104604` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of irinotecan (and liposomal irinotecan), tislelizumab and capecitabine in colorectal cancer, run by Affiliated Cancer Hospital of Shantou University Medical College, now recruiting.

## Summary

Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement is a phase 2, interventional study registered as NCT07104604 by Affiliated Cancer Hospital of Shantou University Medical College, with a registry enrolment figure of 51 participants, started 2025-10-20 and due to reach its primary completion in 2027-03-31. Interventions recorded: Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy. Conditions listed: Rectal Cancer. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: "* Biopsy-confirmed pMMR (proficient mismatch repair) localized advanced low rectal adenocarcinoma (tumor's lower edge ≤ 10 cm from the anus)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07104604
- Phase: 2
- Setting: Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
- Sponsor: Affiliated Cancer Hospital of Shantou University Medical College
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT07104604: https://clinicaltrials.gov/study/NCT07104604

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07104604.json